Attivare Therapeutics to Present Preclinical Data for ATT-01 and ATT-02 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Attivare Therapeutics, Inc., an innovative oncology company focused on the development of its ATTimmune biomaterial scaffold cancer therapies to treat patients across a range of solid and liquid tumors with significant unmet medical needs, today announced it will present preclinical data for its novel ATT-01 and ATT-02 therapeutics in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025.
Attivare Therapeutics Appoints David Sherris, Ph.D. as President, CEO, and Chairman
Attivare Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering new treatments for cancer and infectious diseases through its innovative immune-activating scaffold platform, ATTimmune, has named David Sherris, Ph.D. the company’s new President, Chief Executive Officer, and Chairman of the Board.
